- Home
- MNTX vs APLT Comparison
MNTX vs APLT Comparison
Compare MNTX & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNTX
- APLT
- Stock Information
- Founded
- MNTX 1993
- APLT 2016
- Country
- MNTX United States
- APLT United States
- Employees
- MNTX N/A
- APLT 37
- Industry
- MNTX Industrial Machinery/Components
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- MNTX Technology
- APLT Health Care
- Exchange
- MNTX Nasdaq
- APLT Nasdaq
- Market Cap
- MNTX 117.4M
- APLT 128.0M
- IPO Year
- MNTX 2005
- APLT 2019
- Fundamental
- Price
- MNTX $5.74
- APLT $1.02
- Analyst Decision
- MNTX Hold
- APLT Buy
- Analyst Count
- MNTX 1
- APLT 6
- Target Price
- MNTX $5.80
- APLT $6.60
- AVG Volume (30 Days)
- MNTX 64.4K
- APLT 10.8M
- Earning Date
- MNTX 11-07-2024
- APLT 11-07-2024
- Dividend Yield
- MNTX N/A
- APLT N/A
- EPS Growth
- MNTX 248.43
- APLT N/A
- EPS
- MNTX 0.46
- APLT N/A
- Revenue
- MNTX $294,775,000.00
- APLT N/A
- Revenue This Year
- MNTX $6.97
- APLT N/A
- Revenue Next Year
- MNTX $12.08
- APLT $5,117.00
- P/E Ratio
- MNTX $12.52
- APLT N/A
- Revenue Growth
- MNTX 1.10
- APLT N/A
- 52 Week Low
- MNTX $3.07
- APLT $1.03
- 52 Week High
- MNTX $9.16
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- MNTX 54.99
- APLT 17.18
- Support Level
- MNTX $5.73
- APLT $1.03
- Resistance Level
- MNTX $5.78
- APLT $1.37
- Average True Range (ATR)
- MNTX 0.02
- APLT 0.19
- MACD
- MNTX -0.01
- APLT -0.08
- Stochastic Oscillator
- MNTX 20.00
- APLT 1.22
About MNTX Manitex International Inc.
Manitex International Inc through its subsidiaries is engaged in the design, manufacture, and distribution of engineered lifting solutions. Its products include boom trucks, truck cranes, and sign cranes. The company's segments include Lifting Equipment and Rental Equipment. It generates maximum revenue from the Lifting Equipment segment. Geographically, it derives majority of its revenue from the United States.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.